

Lumula Biochemical

Lumula

CATALOG #
AAA227328


PRODUCT SYNONYMS

Lumula; Lumula biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
Antibacterial agent 60, CAS 1426572-68-0



Structure
Antibacterial agent 60, CAS 1426572-68-0

ADDITIONAL INFORMATION

Related Product Information for Lumula biochemical	There are currently four prostaglandin (PG) derivatives which have been approved for human clinical use for the treatment of glaucoma. The names of the PGs and the concentrations of the approved doses are: travoprost (40 ug/ml), latanoprost (50 ug/ml), bimatoprost (300 ug/ml), and unoprostone (1,500 ug/ml). All of these compounds are modified at C-1 in order to act as lipophilic prodrugs in the eye. All have also been postulated to function via activation of the prostanoid FP receptor. Unoprostone and bimatoprost stand out in this class due to their lack of potency. Both are also claimed to have alternate mechanisms of actions: as a "docosanoid" in the case of unoprostone and as a "prostamide" in the case of bimatoprost. Lumula is a hybrid eicosanoid analog which incorporates the "docosanoid" features of unoprostone as well as the "prostamide" features of bimatoprost. Based on classical structure-activity relationships which have been established for prostanoid receptors
References	1. Sachin Bhagwat, et al. 1,6- diazabicyclo [3,2,1] octan- 7 - one derivatives and their use in the treatment of bacterial infections.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

